Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Placebo-controlled Randomized Trial to Evaluate the Efficacy and Safety of GNR-038 in Comparison With Berinert for Acute Attacks Relief in Patients With Hereditary Angioedema

X
Trial Profile

A Placebo-controlled Randomized Trial to Evaluate the Efficacy and Safety of GNR-038 in Comparison With Berinert for Acute Attacks Relief in Patients With Hereditary Angioedema

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II/III

Latest Information Update: 08 Feb 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GNR 038 (Primary) ; Complement C1 inhibitor protein
  • Indications Hereditary angioedema
  • Focus Registrational; Therapeutic Use
  • Sponsors GENERIUM Pharmaceuticals
  • Most Recent Events

    • 21 Jan 2022 Status changed from not yet recruiting to withdrawn prior to enrolment since company pipeline revision.
    • 25 Oct 2021 Planned initiation date changed from 1 Jun 2021 to 1 Dec 2021.
    • 26 May 2021 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top